Premium
Association of Ultrasonographic Findings of Synovitis With Anti–Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Patients With Palindromic Rheumatism During Active Episodes
Author(s) -
Chen Hsin-Hua,
Lan Joung-Liang,
Hung Guo-Dung,
Chen Yi-Ming,
Lan Howard Haw-Chang,
Chen Der-Yuan
Publication year - 2009
Publication title -
journal of ultrasound in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.574
H-Index - 91
eISSN - 1550-9613
pISSN - 0278-4297
DOI - 10.7863/jum.2009.28.9.1193
Subject(s) - medicine , synovitis , rheumatoid factor , rheumatoid arthritis , rheumatism , antibody , odds ratio , gastroenterology , immunology
Objective. The purpose of this study was to investigate whether the presence of ultrasonographic findings of synovitis is associated with the presence of anti–cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor (RF) in patients with palindromic rheumatism (PR) during active episodes. Methods. Clinically involved regions of 84 patients with PR during active episodes were examined with high‐resolution ultrasonography. Serum levels of anti‐CCP antibodies were determined by an enzyme‐linked immunosorbent assay, and RF levels were measured by nephelometry. Results. Thirty patients (36%) had ultrasonographic findings of synovitis during active episodes. Significantly higher positive rates of anti‐CCP antibodies and RF were observed in patients with PR who had ultrasonographic findings of synovitis compared with those who had no ultrasonographic findings of synovitis (26.7% versus 5.6%; odds ratio, 6.18; P < .05; and 30.0% versus 5.6%; odds ratio, 7.29; P < .01, respectively). The intraobserver and interobserver agreement for the detection of synovitis and Doppler signals by ultrasonographic assessment was excellent. Conclusions. Ultrasonography is a reliable method for assessing the presence of synovitis in patients with PR during active episodes. The ultrasonographic findings of synovitis are associated with the presence of anti‐CCP antibodies and RF in patients with PR.